Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AstraZeneca Says High-level Results From Bax24 Phase 3 Trial Showed Baxdrostat Demonstrated A Statistically Significant And Highly Clinically Meaningful Reduction In Ambulatory 24-hour Average Systolic Blood Pressure Compared With Placebo At 12 Weeks

Author: Benzinga Newsdesk | October 07, 2025 05:23am

Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care. Baxdrostat was generally well tolerated, with a safety profile consistent with the BaxHTN trial.

Posted In: AZN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist